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Abstract 
Background: After the discovery that cell-free fetal DNA (cffDNA) is circulating in the maternal plasma of pregnant 
women, non-invasive prenatal diagnosis for fetal RhD in maternal plasma in RhD negative women at risk for haemo-
lytic disease of the newborn (HDN) was clinically established and used by many laboratories. The objectives of this 
study are: (a) to assess the feasibility and report our experiences of the routine implementation of fetal RHD genotyp-
ing by analysis of cffDNA extracted from maternal plasma of RhD negative women at risk of HDN, and (b) to estimate 
the RhD phenotype frequencies, the RHD genotype frequencies and the RhD zygosity in the Cypriot population.
Methods: cffDNA was extracted from maternal plasma of 73 RhD negative pregnant women. Real-Time Multiplex-
PCR was used to amplify regions of RHD gene in exons 4, 5 and 10. RhD phenotypes were determined on 445 random 
samples using conventional agglutination slide test.
Results: The fetus was predicted to be positive in 53 cases and negative in 18 cases. Two of cases were identified 
as D-variants, weak D type-1 and 11. The frequency of RhD negative homozygosity in the Cypriot population was 
estimated to be 7.2 %, while the frequencies of RHD hemizygosity and RhD positive homozygosity was calculated to 
be 39.2 and 53.6 %, respectively.
Conclusion: Fetal RHD genotyping can be accurately determined using cffDNA from maternal plasma. The imple-
mentation of the test has eliminated all use of unnecessary anti-D and reduced the total use of anti-D by 25.3 % while 
achieving appropriate management of the RhD negative pregnancies.
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Background
The discovery that during pregnancy fetal DNA is cir-
culating in maternal plasma and constitutes about 10 % 
of the total plasma DNA has opened up new avenues in 
non-invasive prenatal diagnosis (NIPD) [1–3]. This dis-
covery led to the development on NIPD for fetal sex and 
fetal RhD during pregnancy [4–7]. The development of a 
reliable and sensitive assay is based on its ability to dis-
criminate fetal DNA from the coexisting background of 
maternal DNA by detecting differences between the two. 
NIPD of fetal sex for X-linked disorders by performing 
real-time PCR using Y chromosome specific targets was 
one of the first clinical applications of NIPD [4, 8]. Soon 
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after, NIPD for fetal RhD in maternal plasma in RhD 
negative women for the identification of pregnancies at 
risk for haemolytic disease of the newborn was clinically 
established and used by many laboratories [9–12].
RHD and RHCE genes located at chromosomal posi-
tion 1p34.1-1p36 encode for the antigens of the Rh 
blood group. The genes are highly homologous encom-
passing 10 exons, while the RHD gene is flanked by two 
homologous DNA segments of the upstream and down-
stream Rhesus boxes [13, 14] (Fig. 1). In Caucasians, the 
RhD negative phenotype is usually caused by a deletion 
of the RHD gene that occurs by an unequal crossing-over 
between the Rhesus boxes leaving only a single hybrid 
Rhesus box [14].
The RhD negative phenotype is most common in Cau-
casians with a frequency of approximately 15 %, less com-
mon in Africans with 8 % frequency and rare in Asians 
with less than 1  % frequency [15]. About 66  % of RhD 
negative Africans have an inactive RHD gene, a pseudo-
gene (RHD*Ψ) that results from a 37-bp insertion in exon 
4 that introduces a stop codon, whereas about 16 % have 
the RHD-CE-Ds hybrid gene [16, 17]. About 0.2–1  % of 
Caucasians have red blood cells with a reduced expres-
sion of the D antigen (weak D) [18]. Single point muta-
tions in RHD which encoding amino acid changes leading 
in a reduced number of D antigen sites on the red blood 
cells, are the main cause of weak D expression [19]. The 
identification of weak D phenotypes and genotyping is of 
clinical importance in terms of transfusion.
RhD negative pregnant women with a hemizygous 
RhD positive partner, have a 50  % chance of having a 
RhD negative fetus. If the fetus is RhD negative, there is 
no need for immunisation. However, if the fetus is RhD 
positive, the RhD negative woman may produce antibod-
ies (alloimmunisation) to the fetal RhD antigens by silent 
fetomaternal haemorrhage during pregnancy, mostly 
during the third trimester and delivery, leading to the life 
threatening haemolytic disease of the fetus and newborn 
(HDFN) in a following pregnancy [20]. The injection of 
anti-D antibodies called Rh-prophylaxis to all RhD nega-
tive pregnant women does prevent this disease in most 
cases. However, many RhD negative women carry a RhD 
negative fetus and, thus, receive anti-D unnecessarily, 
exposing them to the risks associated with administra-
tion of human blood products that have been associated 
with serious viral infections in the past [21].
The clinical application of the non-invasive test for fetal 
RhD typing was implemented soon after the discovery of 
circulating fetal DNA. NIPD of fetal RHD from maternal 
plasma of RhD negative mothers is considered a valuable 
Fig. 1 Schematic structure of the RHD locus. a Normal RhD positive individuals. b RhD negative individuals. c RHD pseudogene. d Hybrid RHD-
RHCE-RHDs gene
Page 3 of 8Papasavva et al. BMC Res Notes  (2016) 9:198 
tool in the identification of pregnancies at risk of HDFN 
and the proper management of these pregnancies, but 
mainly avoiding unnecessary routine RhD prophylaxis 
[22–24]. Since 2001, NIPD of fetal RHD has already been 
offered to pregnant women with RhD positive partners 
as a routine clinical service by the International Blood 
Group Reference Laboratory [25] with other European 
countries following [10, 26–29].
This report discusses our experiences of the routine 
implementation in clinical practice of fetal RhD genotyp-
ing from the maternal plasma of RhD negative mothers 
in Cyprus. NIPD of fetal RHD was performed on mater-
nal plasma on 71 RhD negative women, referred by their 
obstetrician during their routine visit, targeting exons 4, 5 
and 10 of the RHD gene using Real Time PCR. The child’s 
RhD phenotype was confirmed serologically after birth. 
There is an indication of a relatively high percentage of 
RhD negative people in the Cypriot population based on 
the empirical observation of the gynecologists. In this 
work, the RhD phenotype frequency was examined and, 
for the first time, the RhD negative frequency was esti-
mated for the Cypriot population, giving an assessment 
of how many couples are at risk for HDN and in turn eli-
gible for NIPD every year.
Methods
Sample collection
Fifty maternal plasma samples from RhD negative preg-
nant women previously typed were sent by the Univer-
sity Medical Center Göttingen in Germany to be used 
for the verification of the NIPD assay already validated 
by the International Blood Group Reference Laboratory. 
Seventy-three RhD negative pregnant women with RhD 
positive partners at risk of HDN were referred by their 
obstetrician, during their routine visit, to the Cyprus 
Institute of Neurology and Genetics for the NIPD of fetal 
RHD using maternal plasma. These women were from 
the entire Cyprus. Nine milliliters of peripheral blood was 
collected in EDTA tubes after the 16th week of gestation.
Peripheral blood from 445 unrelated adults of both 
sexes, 222 males and 223 females, were drawn into EDTA 
tubes for the determination of RhD phenotype. All par-
ticipants were Greek Cypriots, β-thalassaemia carriers 
referred to the Cyprus Institute of Neurology and Genet-
ics between the period 2009–2010 for β-thalassaemia 
prenatal diagnosis purposes from the entire Cyprus. 
β-thalassaemia trait is not associated with RhD expres-
sion inheritance since the genes are located in different 
chromosomes.
Written informed consent was obtained from all mater-
nal plasma samples from RhD negative pregnant women 
sent by the University Medical Center Göttingen in Ger-
many for validation purposes. RhD negative pregnant 
women included in the study provided informed consent 
for the routine clinical analysis, Non-Invasive Prenatal 
Determination of Fetal RHD in maternal plasma. The test 
is approved by the Board of Directors of the CING and 
accredited by CYS EN ISO 15189:2007. All whole blood 
samples were collected as part of a routine patient care 
after the request of the participants. The study was per-
formed as part of our diagnostic services.
DNA isolation
For the isolation of cell-free maternal plasma from whole 
blood, the samples were subjected to centrifugation 
at low speed, 2500g for 10  min without brake. Subse-
quently, maternal plasma was transferred to microcentri-
fuge tubes and subjected to a second centrifugation step 
at 16,000g for 40  min to remove any residual cells. The 
maternal plasma was carefully removed and transferred 
into polypropylene cryogenic vials in 1  ml aliquots and 
stored at −20 °C until further processing.
Cell-free DNA was extracted from 1  ml of maternal 
plasma before DNA analysis using QIAamp Circulat-
ing Nucleic Acid Kit (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s instructions.
Genomic DNA was isolated from 1  ml of peripheral 
blood using the Puregene Blood Core Kit C (Qiagen Sci-
ences, Germantown, MD, USA).
RhD phenotyping
RhD antigen testing was performed by conventional slide 
test using anti-D murine monoclonal blend, Molter-
clone (Ortho Clinical Diagnostics, Inc., Raritan, NJ). 
The phenotyping test was performed on 445 randomly 
selected samples from the Greek Cypriot population. The 
genotype frequencies and zygosity were calculated, as 
described in the “Results” section.
Fetal RhD Genotyping using real time polymerase chain 
reaction (PCR)
The NIPD assay for fetal RhD implemented at our lab has 
been designed, validated and applied by Finning et al. at 
the International Blood Group Reference Laboratory in 
Bristol [22, 25]. Verification of the assay was performed 
by using fifty maternal plasma samples from RhD nega-
tive pregnant woman, previously typed and sent by the 
University Medical Center Göttingen in Germany. Real 
Time multiplex PCR was used to amplify the regions of 
RHD gene in exons 4, 5, and 10, using 4 replicates per 
exon per sample (Fig.  1). The exon 4 and 5 assays are 
designed to amplify only RHD and not RHD*Ψ. Ampli-
fication of the SRY gene on the Y chromosome is used to 
confirm the presence of male fetal DNA. Amplification of 
the CCR5 gene, common to mother and fetus, is used to 
evaluate the efficiency of the DNA extraction procedure 
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and to estimate the total quantity of DNA (both maternal 
and fetal) present in maternal plasma. Four replicates for 
each exon are performed in order to improve sensitivity 
and to verify the accuracy of the fetal RhD status. Dur-
ing each run, genomic DNA from RhD negative female 
as well as RhD positive male were used for negative and 
positive control respectively. DNA sample from a person 
having the RHD pseudogene was also incorporated in the 
assay to exclude the possibility of someone carrying the 
pseudogene. Moreover, genomic DNA from the parents 
was also included for genotyping in order to confirm the 
phenotype.
Multiplex ligation‑dependent probe analysis (MLPA)
To identify RHD-variants in two pregnant women, the 
MLPA assay was performed as previously described [30]. 
The MLPA fragments were analysed using a 3130 Genetic 
Analyzer (Applied Biosystems) and Genemarker software 
version 1.85 (Softgenetics, State Collage, USA). A DNA 
sample with a RhD positive phenotype and an artificial 
control sample consisting of a mixture of a human cell 
line and plasmid DNA, containing all targets within the 
MLPA assay were used as controls.
Statistical analysis
The data were analysed using the R programming lan-
guage (version 3.1.2). Descriptive statistics were utilised 
for the analysis, while the confidence intervals (CI) were 
defined using the exact binomial test (function binom.
test() in R). In cases where no negative effects were 
observed, such as the method’s accuracy, the 95 % CI was 
estimated using the rule of three [31].
Results
Determination of RHD allele frequencies in Cyprus
Random samples from 445 people from the Greek Cyp-
riot population were tested serologically using standard 
haemagglutination assays to examine the phenotype 
and to determine the frequency of the RhD status in 
the Cypriot population. It was found that 32 individu-
als showed no agglutination with the RhD antigen, thus 
having negative RhD phenotype. The 32 RhD negative 
identified individuals were confirmed using PCR with 
restriction fragment length polymorphism (PCR–RFLP) 
as previously described [32]. The other 413 samples dem-
onstrated positive agglutination and hence RhD positive 
(Table 1). Therefore, 7.2 % of the population in Cyprus is 
RhD negative (95 % CI 4.97–10.00 %). Using the Hardy–
Weinberg equation, p2 + 2pq + q2 = 1 with q2, = 0.0719 
(95  % CI 0.0497–0.1), the homozygous RHD, p2, is cal-
culated to be 0.536 (95  % CI 0.468–0.604). Similarly, 
the hemizygous RhD frequency, 2pq, is calculated to be 
0.392 (95  % CI 0.347–0.433). These data were used to 
determine the RHD zygosity, z, which is defined as the 
fraction of hemizygous RHD samples over the homozy-
gous RHD plus hemizygous RHD samples given by:
The frequency of individuals that are RHD hemizygous 
would be 42 % (95 % CI 36–48 %) among individuals that 
are RhD positive. Based on this result, a couple with the 
mother being homozygous RHD negative and the father 
hemizygous RHD positive has a 21 % (95 % CI 18–24 %) 
reproductive chance of having a child homozygous RHD 
negative and, therefore, not at risk of HDFN since the 
newborn will share the same genotype with the mother. 
As a result, these women take unnecessary immunoglob-
ulin treatment.
NIPD for Fetal RhD using Real Time Polymerase Chain 
Reaction
The RhD status of the fetus in 71 pregnancies was deter-
mined by real-time PCR using fetal DNA derived from 
maternal plasma. If no RHD signals are obtained for 
exons 4, 5 and 10, the fetus is determined to be RhD 
negative. The fetus is determined as RhD positive when 
at least two positive signals are obtained from each RHD 
exon plus a total of three more positive signals from any 
exon. No grey zone results were observed. The presence 
of the maternal DNA was observed in all cases. Based on 
the above criteria, the fetus was predicted to be positive 
in 53 cases and negative in 18 cases (Table 2). As a result, 
these women did not receive any anti-D prophylaxis and, 
therefore, a 25.3  % reduction in anti-D prophylaxis was 
achieved. Moreover, a better and closer monitoring was 
provided to the RhD positive pregnancies.
z =
hemizygousRHD
hom ozygousRHDpositive + hemizygousRHD
Table 1 RhD phenotype frequencies in  445 randomly 
selected samples from the Greek-Cypriot population
RhD determination No. Frequencies (%) 95 % CI
RhD positive 413 92.81 90.00–95.03
RhD negative 32 7.19 4.97–10.00
Total 445
Table 2 NIPD of fetal RHD on maternal plasma of RhD neg-
ative pregnant women





on the newborn’s  
phenotype
Positive 53 (74.6) 53
Negative 18 (25.3) 18
Total 71 71
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Identification of D variant cases
During the routine fetal RhD genotyping two discrep-
ancies were observed. In both cases, the mother, being 
serologically negative was referred to us for NIPD of fetal 
RhD from maternal plasma. However, upon genotyp-
ing the maternal genomic DNA sample with Real Time 
PCR, RHD sequences were detected in the mother’s sam-
ple indicating that the mother is RhD positive. In order 
to confirm this discrepancy, PCR-Restriction Enzyme 
Digestion was also performed on the maternal genomic 
DNA samples to test for RhD zygosity. Both cases were 
found to be hemizygous. Therefore, with the aim of 
investigating these serologic discrepancies in RhD typing, 
the samples were referred to Sanquin center in Amster-
dam to investigate for possible RhD variants. Multiplex 
Ligation Probe Amplification (MLPA) was performed on 
both samples where it was found that sample 1 was weak 
D type 1/d Cc ee (RHD*01 W.01) having the nucleotide 
change 809T > G, while sample 2 was weak D type 11/d 
Cc ee (RHD*11) with nucleotide change 885G > T. These 
D variants have a reduced expression of the RhD antigen 
that arise from single point mutations on the RHD gene 
encoding amino acid changes and, hence, no agglutina-
tion is performed explaining the negative serology result. 
Therefore, NIPD cannot be performed on these sam-
ples since RHD sequences are present in the mother’s 
genome.
Confirmation of fetal RhD status
Serological tests on the infant’s red blood cells (RBCs) 
were performed and RhD type was confirmed after deliv-
ery on all samples tested after contact with the referring 
physician and receipt of written confirmation of the new-
born’s serological analysis (Table 2). When compared to 
postpartum serological results, an accuracy rate of 100 % 
(95 % CI 95.3–100 %) was achieved in our prenatal pre-
diction of fetal RhD status. No false negative or false pos-
itive results were obtained on the 71 samples that were 
cross checked.
Discussion
In this study, we have determined the RhD phenotype 
status of 445 random samples in an attempt to establish 
the frequency of the RHD negative allele in the Cypriot 
population. As a result, the frequency of the RhD nega-
tive phenotype in the Cypriot population is found to be 
7.2 % (95 % CI 5–10 %), a value that is demonstrated to 
be different from that reported in the literature where it 
is stated that about 15  % of Caucasians do not express 
the RhD antigen. However, it is more consistent with 
8.59 % frequency reported for the Greek population [33]. 
In non-European populations the frequency of the RhD 
negatives is much lower than Caucasians with Africans 
having 8 %, higher than the Cypriots, and Asians 1 % [15].
It is reported that in western European populations the 
frequency is greater, the highest for instance of 21–36 % 
in the Basque French population [34]. The determina-
tion of the frequency of RHD negative alleles in Cyprus 
it is also important as it gives an indication, of how 
many couples are at risk for HDFN, a number that dif-
fers from what applies to Caucasians, and therefore in 
need for the prenatal determination of fetal RHD with 
maternal plasma. The determination of the paternal RHD 
zygosity is valuable in clinical setting as it can aid in the 
assessment of a couple’s risk of carrying a RhD posi-
tive child and in turn in risk of HDFN related to anti-D. 
The reported frequency of RHD hemizygosity would be 
around 56 % [35], for the Caucasians, however our study 
demonstrated a frequency zygosity value of 42 % among 
individuals that are RhD positive, in the Cypriot popula-
tion, a value that is consistent with the lower RhD nega-
tive phenotype observed. Based on our results, fathers 
who are RHD positive have a 21  % predicted chance of 
a homozygous RhD negative fetus. Hemizygous RHD 
males have a 50 % chance of having a RhD negative off-
spring, in which case the pregnancy will not be at risk for 
HDFN.
Several studies have demonstrated the feasibility and 
accuracy of prenatal determination of fetal RHD with 
maternal plasma. A number of centers worldwide have 
reported the introduction of the test in their clinical 
practice. We have also applied the non-invasive fetal 
RhD genotyping in maternal plasma in a routine diag-
nostic setting in our lab and we have tested 71 samples 
since 2009. Our results were confirmed with the serolog-
ical test on the newborns red cells on all samples tested. 
With the implementation of this method into routine 
clinical practice, we have achieved 25.3  % reduction in 
the administration of anti-D since 18 out of the 71 RhD 
negative women were predicted to have a RhD nega-
tive fetus. The observed difference, although relatively 
close, between the achieved value of 25.3 %, and the pre-
dicted one, 21 %, could be related to the small number of 
maternal plasma samples analysed compared to the 445 
samples from which the predicted value was derived. 
Nevertheless, the implementation of the non-invasive 
fetal RhD testing and the high accuracy rate achieved is 
of paramount importance as it allows targeting immu-
noprophylaxis only to RhD negative pregnant women 
carrying an RhD positive fetus. Therefore, unnecessary 
administration of Ig anti-D to those carrying RhD nega-
tive fetus is avoided. Moreover, the implementation of 
this test not only serves as an important tool for ante-
natal diagnosis of fetomaternal incompatibility but also 
allows for a better follow-up and management of anti-D 
immunised women.
Page 6 of 8Papasavva et al. BMC Res Notes  (2016) 9:198 
Based on our RhD phenotyping results, around 600 
pregnancies per year in Cyprus are at risk for HDNF 
(RhD negative pregnant women with RhD positive part-
ners), therefore eligible for NIPD for fetal RhD. It was 
observed, however, that the actual implementation 
of the programme into routine practice was slow with 
an initial number of samples far below the expected 
number. This might be attributed to the fact that this a 
fairly new test and currently the cost is not covered by 
the national health system. Moreover, clinicians some-
times are skeptical in embracing and adopting a new 
approach. We anticipate that with continuous educa-
tion and a possible health care system that will cover the 
cost, an improvement in participation of more samples 
will be achieved.
Two out of the 73 samples referred for NIPD were 
identified as RhD variants, specifically weak D type 1 and 
11. Weak D types result from nucleotide changes that 
encode amino acid substitutions in the membrane or 
below the membrane of the RhD polypeptide [36]. These 
changes affect the efficiency of insertion and, in turn, 
the quantity of RhD protein in the membrane reducing 
the number of RhD antigen sites on the red blood cells 
[19] leading to lack of reactivity with anti-D, no aggluti-
nation is performed supporting the RhD negative phe-
notype. Although the haemagglutination assay shows a 
sensitivity and specificity of 99.5–100 %, it is accepted in 
the literature that weak D units may escape detection by 
serologic methods. However, serology is still widely used 
to assign RhD negative or RhD positive patient [37–39].
An estimated 0.2–1 % of Caucasians carry red cells with 
a reduced expression of the RhD antigen (weak D) [18, 
39] as reported in the literature. Our experience shows 
that about 2.7 % (95 % CI 0.33–9.55 %) of RhD negative 
women carry a weak D type genotype, but a larger sam-
ple size is needed to determine whether this difference is 
significant. Weak D types 1–4 represent more than 90 % 
of all weak D occurring in Europeans [40]. Appropriate 
assignment of RhD antigen status is critical since com-
mercially available anti-D reagents react differently with 
D variants. Patients with a weak D type 1 are treated as 
RhD positive, therefore transfused with RhD positive 
RBCs and as a result RhIg is not administered to preg-
nant women. On the other hand weak D type 11 should 
be treated as RhD negative, transfused with RhD nega-
tive RBCs and therefore RhIg is administered to pregnant 
women [19, 30, 40]. The above haemotherapy approach 
is in accordance with guidelines in Europe [40], however, 
in Cyprus there are no guidelines, since all weak D types 
are managed as RhD negative. The identification of weak 
D types and their classification will assist in the develop-
ment of a more efficient guidance and management of an 
RhD negative transfusion policy in Cyprus. Therefore, a 
collaborative study with all the relevant health care offi-
cials is highly recommended.
Conclusions
In this study, we have demonstrated the diagnostic accu-
racy of our NIPD test for identification of the fetal RhD 
status in maternal plasma and its importance in manag-
ing the RhD negative pregnancies. We have also demon-
strated that the introduction of this test in clinical setting 
has eliminated the use of unnecessary anti-D and reduced 
the total use of anti-D by 25.3 %. Through the study, RhD 
variants were identified and defined. Moreover, we have 
estimated the RhD phenotype frequencies in the Cypriot 
population to be 7.2 % (95 % CI 5–10 %) for RhD nega-
tive and 92.8 % (95 % CI 90–95 %) for RhD positive. In 
addition, we have calculated the RHD genotypes in the 
Cypriot population to be 53.6  % (95  % CI 46.8–60.4  %) 
for RHD positive homozygous and 39.2 % (95 % CI 34.7–
43.3 %) for RHD hemizygous. Finally, it is recommended 
that a systematic and targeted prevention based on fetal 
RhD genotyping from maternal plasma should be evalu-
ated to define the impact and potential benefits on man-
agement, and quality of life.
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